Piper Jaffray Reiterates Overweight, PT of $29 on Mindray Medical

Loading...
Loading...
Piper Jaffray maintains its Overweight rating and $29 target price on Mindray Medical
MR
on incremental positive developments towards China growth. Piper Jaffray says, “Mgmt expressed confidence in China's growth momentum, driven by government-driven county-level build-up/upgrade. MR's recent distribution adjustment (from 1,000 to 700) and sales force reinforcement, as well as key account strategies, all highlight the company's focus to have a better sales execution and extract bundled sales at more efficient level.” MR closed at $26.98 per share on Wednesday.
Posted In: Analyst ColorReiterationAnalyst RatingsPiper Jaffray
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...